What is in it for my patient? Moving beyond short-term benefits and risks for recently approved DMTs in MS
25 November 2021

What is in it for my patient? Moving beyond short-term benefits and risks for recently approved DMTs in MS

Join Prof. Gavin Giovannoni, Prof. David Baker and Prof. Sonia Batista for the next interactive multiple sclerosis seminar of Janssen’s Neuroscience Medical Education (NSME) Forum. Here, the faculty will reflect on the therapeutic potential of new disease-modifying therapies (DMTs) for MS and discuss based on clinical scenarios what it means for patients in practice. This ...

more info...

EM-72360
;